[go: up one dir, main page]

EA200801676A1 - Комбинация производных триазина и сенсибилизаторов инсулина - Google Patents

Комбинация производных триазина и сенсибилизаторов инсулина

Info

Publication number
EA200801676A1
EA200801676A1 EA200801676A EA200801676A EA200801676A1 EA 200801676 A1 EA200801676 A1 EA 200801676A1 EA 200801676 A EA200801676 A EA 200801676A EA 200801676 A EA200801676 A EA 200801676A EA 200801676 A1 EA200801676 A1 EA 200801676A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combination
triazine derivatives
insulin sensitizers
sensitizers
insulin
Prior art date
Application number
EA200801676A
Other languages
English (en)
Other versions
EA015576B1 (ru
Inventor
Жерар Муэне
Даньель Краво
Дидье Месанжо
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA200801676A1 publication Critical patent/EA200801676A1/ru
Publication of EA015576B1 publication Critical patent/EA015576B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к комбинациям производных триазина и сенсибилизаторов инсулина.
EA200801676A 2006-01-13 2006-12-18 Комбинация производных триазина и сенсибилизаторов инсулина EA015576B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0600344A FR2896159B1 (fr) 2006-01-13 2006-01-13 Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
PCT/EP2006/012185 WO2007079917A2 (en) 2006-01-13 2006-12-18 Combination of triazine derivatives and insulin sensitisers

Publications (2)

Publication Number Publication Date
EA200801676A1 true EA200801676A1 (ru) 2008-12-30
EA015576B1 EA015576B1 (ru) 2011-10-31

Family

ID=36654309

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801676A EA015576B1 (ru) 2006-01-13 2006-12-18 Комбинация производных триазина и сенсибилизаторов инсулина

Country Status (22)

Country Link
US (2) US8791115B2 (ru)
EP (1) EP1971330B1 (ru)
JP (1) JP5249782B2 (ru)
KR (2) KR20140033498A (ru)
CN (1) CN101355933A (ru)
AR (1) AR059032A1 (ru)
AT (1) ATE476179T1 (ru)
AU (1) AU2006334734B2 (ru)
BR (1) BRPI0620985B8 (ru)
CA (1) CA2640897C (ru)
CY (1) CY1110789T1 (ru)
DE (1) DE602006016014D1 (ru)
DK (1) DK1971330T3 (ru)
EA (1) EA015576B1 (ru)
ES (1) ES2347177T3 (ru)
FR (1) FR2896159B1 (ru)
IL (1) IL192558A (ru)
PL (1) PL1971330T3 (ru)
PT (1) PT1971330E (ru)
SI (1) SI1971330T1 (ru)
WO (1) WO2007079917A2 (ru)
ZA (1) ZA200806947B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
AU2009326965A1 (en) * 2008-12-12 2011-06-23 Poxel Tetrahydrotriazine compounds for treating diseases associated with AMPK activity
ES2530223T3 (es) * 2008-12-12 2015-02-27 Poxel S.A.S. Combinación de insulina con derivados de triazina y su uso para tratar la diabetes
FR2948026B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
TWI436768B (zh) * 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
KR20120011667A (ko) * 2010-07-29 2012-02-08 광주과학기술원 당뇨병 치료제의 스크리닝 방법
KR101271218B1 (ko) * 2012-12-07 2013-06-07 광주과학기술원 당뇨병 치료제의 스크리닝 방법
MX2020003243A (es) 2017-10-02 2020-09-18 Poxel Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
ES2929994T3 (es) 2018-06-06 2022-12-05 Poxel Sa Métodos de tratamiento de sujetos que padecen diabetes con enfermedad renal crónica
WO2019238647A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
US5885980A (en) * 1996-06-25 1999-03-23 Enrique G. Gutierrez Composition and method for treating diabetes
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
EP1278513B1 (en) * 2000-05-01 2007-07-18 Aeropharm Technology, LLC A core formulation
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
AR048282A1 (es) * 2003-08-01 2006-04-19 Janssen Pharmaceutica Nv Indol- o - glucosidos sustituidos
FR2863484B1 (fr) * 2003-12-11 2007-04-13 Oreal Utilisation de composes capables d'agir sur la voie metabolique controlee par la dopachrome tautomerase trp-2 comme agent protecteur des melanocytes du follicule pileux et applications
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.

Also Published As

Publication number Publication date
IL192558A (en) 2013-04-30
PT1971330E (pt) 2010-09-09
AR059032A1 (es) 2008-03-12
KR101482685B1 (ko) 2015-01-14
ZA200806947B (en) 2009-11-25
US20140050786A1 (en) 2014-02-20
AU2006334734B2 (en) 2012-07-19
FR2896159B1 (fr) 2008-09-12
KR20140033498A (ko) 2014-03-18
JP5249782B2 (ja) 2013-07-31
KR20080088630A (ko) 2008-10-02
EP1971330B1 (en) 2010-08-04
CY1110789T1 (el) 2015-06-10
US20100285117A1 (en) 2010-11-11
CA2640897A1 (en) 2007-07-19
AU2006334734A1 (en) 2007-07-19
BRPI0620985A2 (pt) 2011-11-29
JP2009523142A (ja) 2009-06-18
PL1971330T3 (pl) 2011-01-31
WO2007079917A3 (en) 2007-08-30
CN101355933A (zh) 2009-01-28
CA2640897C (en) 2015-10-20
BRPI0620985B1 (pt) 2020-04-28
EP1971330A2 (en) 2008-09-24
DE602006016014D1 (de) 2010-09-16
EA015576B1 (ru) 2011-10-31
DK1971330T3 (da) 2010-10-25
ATE476179T1 (de) 2010-08-15
SI1971330T1 (sl) 2010-11-30
BRPI0620985B8 (pt) 2021-05-25
FR2896159A1 (fr) 2007-07-20
ES2347177T3 (es) 2010-10-26
US8791115B2 (en) 2014-07-29
WO2007079917A2 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
DK1874821T3 (da) Kombination af antistoffer med glykokortikoider til behandling af kræft
EA201790678A1 (ru) Бициклические гетероарильные соединения
EA201170227A1 (ru) Имидазолкарбоксамиды
EA201270254A1 (ru) Производные 5-фторпиримидинона
MA32508B1 (fr) Composes organiques
BRPI0915084B8 (pt) composto, e, composição farmacêutica
FR2918570B1 (fr) DIGLYCATION DES AGEs.
EA201070519A1 (ru) Соединения тропана
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида
BRPI0812222A2 (pt) Compostos ciclobutenodiona substituídos anti-inflamatórios.
EA201270255A1 (ru) 5-фтор-2-оксопиримидин-1(2h)-карбоксилатные производные
BRPI1010887A2 (pt) derivados de triazina e suas aplicações terapêuticas.
EA201270253A1 (ru) Производные n1-ацил-5-фторпиримидинона
EA200870515A1 (ru) Моноциклические гетероарильные соединения
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
EA201201623A1 (ru) Лечение диабета 2 типа
MX373170B (es) Variantes de la familia il-1.
DE602006019624D1 (de) Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors
EA200801676A1 (ru) Комбинация производных триазина и сенсибилизаторов инсулина
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
EA201101195A1 (ru) Производные розувастатина и аторвастатина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM